NightingaleFor Academic Medical Centers and Site Networks
For research teams, hospitals and site networksLive at Emory University

Run better studies on the data you already collect.

Nightingale connects the systems your study already runs on, checks and cleans every value as it arrives, and delivers it to the study database with a full audit trail. Your coordinators confirm values instead of retyping them.

Epicvia patient-approved access
Minutesfrom event to dataset
AnyEHR, device or lab
GxPaudit complete
Yoursdata stays with you
01 · Why data is the bottleneck

The study design is rarely the hard part. The data collection is.

Coordinators and fellows spend their time moving numbers between systems, and the study waits on them.

8.1 days
from a patient visit to data in the study database 3
8.23%
error rate when a person re-keys a record by hand 5
~69%
of sites work across six or more study systems 4
~12 hrs
a week per data manager on queries and cleanup 9

What investigators tell us

Decisions wait on data

Information that could guide care or monitoring arrives a day or more after the event.

Dashboards stop at what the system reports

Quality metrics inside the hospital are limited to what existing reporting exposes.

Cross-institution studies stall

Fragmented pipelines and separate review processes make multi-site collection the hardest part.

Funding is tight outside oncology

Studies in other specialties compete for smaller pools, so data work has to be cheap and reusable.

02 · Trials in scope

How many trials this applies to.

How many studies a year this applies to, counted from the public registry rather than estimated from market reports.

35,000+
new studies registered every year 13
~20,000
interventional trials a year we can serve, our estimate 13
~28.5%
of interventional trials are industry-sponsored; the rest are academic, hospital or government 21
Every phase
Phase I to IV, plus device, diagnostic and software studies
In scope

Interventional trials of any phase, and device, diagnostic or digital-health studies, that collect data from more than one electronic source and report into a study database.

Best fit today

Studies with wearables, home visits, several labs or many sites, where reconciling sources by hand is the bottleneck.

Out of scope

Registry-only and observational studies with a single data source, where there is little to reconcile.

The trial pool keeps growing: registrations have risen every year since the registry opened in 2000 13. Counts are from public registry data; the in-scope figure is our estimate, not a registry statistic.

03 · How it works

One pipeline from your systems to the study database.

Nightingale reads your existing systems, checks the study documents against each other, cleans and standardizes every value, and delivers it with an audit trail. Sites keep their current workflow.

WHAT GOES INNIGHTINGALE · RUNS FOR THE WHOLE TRIALWHAT COMES OUT The study's rulebook Protocol · endpoints Lab & pharmacy manuals Consent · questionnaires Data-entry guide · output spec The regulators' rulebook FDA guidance · Part 11 EMA (EU) · ICH E6(R3) The data · each site's own Hospital records (EHR) Labs · imaging · pharmacy Wearables · devices · apps Telehealth visits Handwritten notes · paper Real-world evidence 1 · Check the rulebook Study documents vs each other vs FDA / EMA / ICH → every conflict flagged 2 · Inventory What already exists, incl. real-world evidence 3 · Find the gap The study's required output vs what exists → what to collect 4 · Run the data · fixed rules map field → convert unit → check range → deliver Same input always gives the same output. No retyping. AI reads documents; fixed rules decide. 5 · Watch it daily Gap re-checked on live data. Advance notice if an endpoint is at risk. 6 · Prove every step Audit trail per data point: created, verified, or fixed & flagged. ↻ steps 4-6 repeat every day until the last data point 7 · Close and submit Endpoints met? If not, why, and what to enroll. Submission-ready package for the regulator. 8 · Every trial feeds the cross-trial data layer Consented, de-identified, identically structured. The basis for Layer 3. Study databaseMedidata · Veeva · Oracle · any Your output formatExactly as specified Audit recordEvery value, every step RegulatorReal-time feed · submission package Storage stays with you. Layer 3 · synthetic control arms · digital twins · cross-trial discovery · new treatments
Hover a stage to trace its inputs and outputs; click to see an example. Every stage produces something you can open and check.
1

Check the rulebook

Every study document vs each other and vs FDA, EMA, ICH. Conflicts flagged before enrollment.

ExampleProtocol in kilometers, lab manual in miles. Flagged on day one, not month four.
2

Inventory what exists

Records, prior labs, device history and paper, filtered to what counts.

ExampleTwo years of blood pressure already in the chart get structured and counted.
3

Find the gap

What the study needs minus what exists = what to collect.

ExampleECGs needed at weeks 4, 12, 24; records cover week 4 for a third of patients.
4

Run the data

Map, convert, check, deliver into the EDC. No retyping.

ExampleWatch reports 10 miles; 16.09 km lands in the right field, with the conversion recorded.
5

Watch it daily

Gap re-checked on live data; early warning when an endpoint is at risk.

ExampleSite 17's ECG timestamps drift 40 minutes. Flagged in week 3, not at lock.
6

Prove every step

An audit trail for every data point, created or verified.

ExampleWhere did this glucose value come from? One click: device, time, conversion, reviewer.
◉AI readsDocuments, notes, scans, photos
▣Rules decideFixed rules you can read. No AI in the pipeline.
✕ Not a database✕ Not a CRO✕ Not a tool for sites✕ Not a regulated device
04 · Your systems

Any source in. Any destination out.

Connections are agreed with your IT team and run on patient-approved access. Nothing is limited to one vendor.

◉Any EHR

Epic, Cerner, Allscripts or anything else your sites run. With the patient's approval, Epic connects through MyChart using its standard data connection and returns the whole chart, not just one clinic's visits. New results come through as they happen, checked at least every five minutes.

◷Any wearable or medical device

CGMs, smartwatches, ECG and other connected devices. Device data comes through the manufacturer's cloud, such as Dexcom Clarity, once the patient consents; devices that pair with a phone app connect directly, and devices that only send to a handheld reader need one extra setup step.

▤Any lab system

LabCorp, Quest, central labs and your hospital lab systems, through connections agreed with your IT team.

≡Any patient-reported outcome system

Patient-reported outcomes, diaries and questionnaires, alongside paper forms and scanned source documents.

Delivered wherever the study keeps its data

▣Your own database

A study database or research data store your team built, in the structure you specify.

▤REDCap

Delivered into REDCap projects, field by field, with the conversions recorded.

◉Any EDC

Medidata Rave, Veeva Vault, Oracle Clinical, Castor and others, in the format the study requires.

≡Submission-ready datasets

In the standard format regulators expect, with the full record behind every value, for FDA or EU requirements.

05 · What it enables

Studies and tools this makes possible.

Pragmatic trials with rolling enrollment

An automated pipeline keeps collection running while enrollment continues and the protocol changes, instead of a fixed extract per amendment.

Real-time data for care decisions

Data arrives in minutes rather than the next day, so it can feed monitoring or a decision-support tool your team builds.

Quality dashboards for leadership

The same clean, structured feed supports quality metrics reporting, which is often easier to fund than a trial.

Multi-site studies

Each site connects its own systems; every site's data lands in one identical structure.

Monitoring inside and outside the hospital

Inpatient records and at-home device data in one dataset, without a separate manual export.

Investigator-initiated studies

The data work that usually needs a coordinator or a data manager is handled by the pipeline.

06 · For coordinators

What your coordinators see at a visit.

One plain screen for visit days. It shows what needs doing, checks the timing and order the protocol sets while the visit happens, and sends checked values into the study database once the coordinator confirms them.

1What needs you today

Today's visits and tasks in plain words, with every visit window counted from Day 1 and anything not booked at the top.

2The visit, step by step

Seated rest before blood pressure, lying down before the ECG, blood before the morning dose, tubes spun in time. A timing problem shows up while the participant is still there.

3Confirm, don't retype

Checked values wait for the coordinator's OK, then go into Rave or whichever EDC the sponsor uses. Nothing is typed twice.

Nightingale for Coordinators: the visit checklist for a Week 12 visit, with the visit clock, check-in questions and the protocol's timing and order rules listed beside it.
The visit checklist in the coordinator demo. Made-up study and patients.

Both demos run on a made-up knee arthritis study. No real patients or sites.

07 · Across institutions

One study, several sites, one dataset.

Every site connects its own systems, and the data arrives in one structure with a single audit trail.

Multi-site study today
Data collectionEach site extracts its own way
FormatsReconciled by hand, late
Adding a siteA new pipeline each time
Audit trailRebuilt per site
With Nightingale
Data collectionOne specification, applied at every site
FormatsStandardized before the data lands
Adding a siteConnect its systems; structure is already set
Audit trailOne record across all sites
08 · Data and compliance

Your data stays with you.

By designYour data stays with you

The preferred model: the institution stores the data, Nightingale operates the pipeline.

CompleteGxP vendor audit

The quality standard regulated life-science vendors are held to.

Aligned21 CFR Part 11

The FDA rule for electronic records.

AlignedICH E6(R3)

An audit trail on every value, from source to submission.

In progressSOC 2 Type II

Independent security audit underway.

SignedHIPAA BAA

Identifiable data minimized and handled only under a signed agreement.

CompletedIRB review

Reviewed through the IRB process at our flagship deployment.

Yours to setCustom rules

Study-specific logic you define, such as flagging possible AKI when creatinine crosses a threshold.

09 · Funding

How this work usually gets paid for.

Nightingale is priced per study on participants, data sources and duration, so the cost is known before the work starts.

Grant-funded studies

Data infrastructure written into the budget of a trial or pragmatic study application.

Quality improvement budgets

Framed around quality metrics and reporting for hospital leadership.

Philanthropy

Institutional or departmental gift funding, where a named study has a clear patient-care case.

Industry-sponsored trials

The sponsor or CRO pays, and the site gets the same clean data with no site-level cost.

10 · How we start

From one study to a portfolio.

How we startFour steps to a first study.
Step 01Study review

A 30-minute call on the study you have in mind, its sites and its data sources.

Step 02Data flow review

A complimentary review of one study: systems, formats, gaps and what the endpoints need.

Step 03Scope and plan

Written findings, the connection plan, and a quote you can put in a budget or a grant.

Step 04Pilot on one study

Connect the sources and run alongside your current process, then compare before expanding.

11 · Where we are today

Live on real patient data.

Flagship deployment

EmpowerMBC at Emory University, a Gilead-funded oncology study, is our live deployment and the reference we will put on a call. We baseline against your current process before claiming anything.

Where we work

$340K contracted across signed agreements: Emory University plus two medical-device trials via Thinq CRO. Harvard iLab company, onboarding into the Georgia CTSA Program, and in conversation with several academic centers about multi-site studies.

12 · Questions

What research teams ask first.

Tap a question for the full answer.
In shortIt sits between your systems and the study database.
In shortYour institution keeps the data. We run the pipeline.
In shortPatient-approved access through standard interfaces, not a manual export.
In shortOne plain screen, and nothing to retype.
In shortReviewed before, with the documentation ready.
In shortPriced per study, in a form you can budget or put in a grant.
13 · Get in touch

Start with one study.

Thirty minutes on the study you have in mind and the systems it would pull from.

Yash Vagal
Co-Founder and CEO, Nightingale

Pick a time that works for you. We will walk through the study, the data sources and what a first connection looks like.

30-minute callVideo call
Book a call

What happens next

1Study review

A 30-minute call on the study and the systems behind it.

2Data flow review

A complimentary review of the sources, formats and gaps.

3Pilot on one study

Connect the sources, then measure against how you run today.

14 · Appendix · sources

Sources behind every figure.

Show all 20 sources
  1. Tufts Center for the Study of Drug Development (2021): Phase III protocols average 3.6 million data points, three times the volume of ten years earlier.
  2. Marra C. et al. (2020), npj Digital Medicine: connected digital products in trials grew ~34% per year, 2000-2017.
  3. Tufts CSDD and Veeva Systems, eClinical Landscape Study (2017): 257 organizations; median 8.1 days from patient visit to EDC entry; 36 days on average from last patient last visit to database lock.
  4. Advarra, Study Activation Survey 2023: N>500 sites; ~69% use six or more sponsor systems.
  5. Garza M. et al. (2026): manual transcription error rate 8.23%; integrated capture showed no detected transcription errors.
  6. Stokman P. et al. (2021), Journal of the Society for Clinical Data Management 1(1), DOI 10.47912/jscdm.20: 20 Phase III studies, 1,939,606 queries; ~96,980 per study; 42% resulted in a data change.
  7. Smith Z., DiMasi J., Getz K. (2024), Therapeutic Innovation & Regulatory Science 58(5):855-862: direct cost of trial delay $55,716/day; opportunity cost on the order of $500,000/day.
  8. Salary.com, US Clinical Data Manager compensation, September 2026: average $144,625, ~$70/hour.
  9. Vendor-sponsored industry survey, n=88: ~12 hours/week per data manager per study on query and reconciliation work. Indicative.
  10. Moore T. et al. (2018), JAMA Internal Medicine: median cost per patient in pivotal trials ~$41,117. Per-source and fixed-cost components are estimates.
  11. IQVIA Institute, Global Use of Medicines: global medicine spending ~$1.6T. Medical device market ~$600B (industry estimate). WHO: global health spending ~$10T.
  12. Evaluate Pharma / IFPMA: pharmaceutical R&D ~$300B per year; medtech and digital-health R&D ~$50B (estimate). IQVIA Technologies, Veeva and Medidata combined revenue ~$10B.
  13. ClinicalTrials.gov: more than 35,000 new studies registered per year. The ~20,000 addressable interventional figure is an estimate.
  14. ClinicalTrials.gov sponsor records: Pfizer ~423 tracked / 251 active; Eli Lilly ~333. Order-of-magnitude proxy.
  15. ICH E6(R3): §3.16.1(c), §3.16.2(c), §2.12. Step 4 6 Jan 2025; EU 23 Jul 2025; FDA 9 Sep 2025; Annex 2 adopted 3 Jun 2026, effective 15 Jan 2027.
  16. FDA Digital Health Technologies guidance (Dec 2023); FDA Part 11 Q&A (Oct 2024); FDA and EMA AI principles (Jan 2026); FDA Real-Time Clinical Trials (28 Apr 2026).
  17. Disclosed transactions: Change Healthcare/Optum $13B; Datavant/Ciox ~$7B; Komodo Health $3.3B; Flatiron Health/Roche $1.9B; Truveta >$1B; Tempus AI market capitalization ~$10.6B.
  18. Public revenue multiples: Snowflake at IPO >100× trailing; Palantir ~80× (2025); Cloudflare ~35× (2025); Databricks ~27× (private, 2025).
  19. Private comparables: a September 2026 software seed round at $7M on $100M post-money with ~$500K lifetime revenue; a clinical-trial software company that raised under $400K in total and sold for roughly half a billion dollars. Details available on request.
  20. FDA, Considerations for the Design and Conduct of Externally Controlled Trials, draft guidance, February 2023. EMA, qualification opinion on prognostic covariate adjustment using digital twins (PROCOVA), September 2022.
  21. Assessment of Trends in the Design, Accrual, and Completion of Trials Registered in ClinicalTrials.gov by Sponsor Type, 2000-2019, JAMA Network Open (2020): of 245,999 interventional studies, 70,329 (28.5%) were industry-sponsored.